These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14584292)

  • 21. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
    Lotan Y
    Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
    [No Abstract]   [Full Text] [Related]  

  • 22. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 25. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'Clandestine' prostate cancer haunts.
    Chapman B
    CAP Today; 1996 Feb; 10(2):1, 34-6, 38 passim. PubMed ID: 10160261
    [No Abstract]   [Full Text] [Related]  

  • 27. [First line indications for hormonal therapy in prostate cancer].
    Boccon-Gibod L; Richaud P; Coloby P; Coulange C; Culine S; Davin JL; Soulié M; Zerbib M
    Prog Urol; 2010 Feb; 20(2):109-15. PubMed ID: 20142051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.
    Wong KW; Ma WK; Wong CW; Wong MH; Tsang CF; Tsu HL; Ho KL; Yiu MK
    Hong Kong Med J; 2016 Apr; 22(2):106-15. PubMed ID: 26635306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 30. PSA response to thalidomide in patients with advanced prostate cancer.
    Leibowitz R; Tucker SJ
    Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine therapy of prostate cancer: optimal form and timing.
    Labrie F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1066-71. PubMed ID: 7714068
    [No Abstract]   [Full Text] [Related]  

  • 33. [Surgery, radiotherapy or hormonal therapy in the treatment of prostate cancer].
    Bonnet P; Coppens L; Andrianne R; Waltregny D; Keppenne V; Leduc F; Fillet M; Ghammad S; de Leval J
    Rev Med Liege; 1999 Nov; 54(11):875-85. PubMed ID: 10667047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunities for targeted focal treatment in Japan.
    Kimura M; Muto S; Horie S
    Curr Opin Urol; 2015 May; 25(3):225-9. PubMed ID: 25700132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gene expression profile in hormone refractory prostate cancer].
    Stoss O; Jost N; Czeloth K; Rüschoff J; Henkel T; Albers P
    Urologe A; 2007 Sep; 46(9):1117-9. PubMed ID: 17639295
    [No Abstract]   [Full Text] [Related]  

  • 37. Endocrine therapy for prostate cancer.
    Labrie F
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An unusual presentation of prostate cancer].
    Joual A; Rabii R; Aboutaeib R; el Moussaoui A; Benjelloun S
    Ann Urol (Paris); 1996; 30(5):262-3. PubMed ID: 8975593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.